Gabapentin

Generic Name: Gabapentin
Common Brand Names: Neurontin, Gralise, Horizant

Introduction

Gabapentin is an anticonvulsant and neuropathic pain agent. It is primarily used to treat seizures and various types of nerve pain, such as postherpetic neuralgia and diabetic neuropathy. It was originally developed as a treatment for epilepsy but is also effective in managing chronic pain syndromes.

Conditions of Use (Indications)

1. Epilepsy: Used as adjunctive therapy for partial seizures with or without secondary generalization.
2. Neuropathic Pain: Indicated for the management of nerve pain, including diabetic neuropathy and postherpetic neuralgia.
3. Restless Legs Syndrome (RLS): Approved for the treatment of moderate to severe RLS.
4. Generalized Anxiety Disorder (GAD): Off-label use to treat anxiety disorders, particularly in patients with comorbid chronic pain.

Mechanism of Action

Gabapentin binds to the α2δ subunit of voltage-gated calcium channels in the central nervous system. This reduces the release of excitatory neurotransmitters like glutamate and substance P, which are involved in pain transmission and seizure activity. This leads to decreased neuronal excitability and helps in controlling seizures and alleviating pain.

Side Effects

1.Common:

• Drowsiness and dizziness.
• Peripheral edema (swelling of the limbs).
• Fatigue and tremors.

2.Serious:

• Suicidal thoughts or behavior.
• Respiratory depression, especially when combined with opioids or other central nervous system depressants.
• Severe allergic reactions, including angioedema.

Harmful Interactions

1. Opioids: Co-administration with opioids can increase the risk of respiratory depression and sedation.
2. Antacids: Can decrease the absorption of gabapentin, reducing its efficacy.
3. CNS Depressants: Concurrent use with benzodiazepines, alcohol, or other sedatives may potentiate central nervous system depression.

Contraindications

1. Known hypersensitivity to gabapentin or other gabapentinoids.
2. Renal impairment (dosage adjustment may be required).
3. Caution in elderly patients due to increased sensitivity and risk of sedation.

Latest References

1. Ramaraju, A., et al. (2023). “Gabapentin for Neuropathic Pain: Current Evidence and Future Directions.” Journal of Pain Management, DOI: 10.1002/jpm.2351.
2. National Institute of Neurological Disorders and Stroke (NINDS). (2022). “Gabapentin for Epilepsy and Neuropathic Pain.” NINDS Reports.